About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
BMY - Bristol-Myers Squibb...| Previous Close | $59.27 | Open | |
| Volume | 94 | Market Cap | 133.883B |
| Yield | 2.96 % | Last Dividend | $1.76 |
| Bristol Myers' Opdivo with Exelixis drug... | 09/18/20 |
| "There is no doubt in my mind that this will be a major player" as an initial treatment for advanced kidney cancer, said lead researcher Dr. Toni Chou... | |
| Bristol Myers' Opdivo with Exelixis drug... | 09/18/20 |
| Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untr... | |
| Bristol Myers Squibb Receives Positive C... | 09/18/20 |
| PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) Plus Y... | |
| Dr Reddy's Labs Hits Record High On Sett... | 09/18/20 |
| Shares of Dr Reddy's Laboratories soared 10 percent to hit a record high of Rs 5,302.85 after the pharma company informed the settlement of their liti... | |
| After win at patent office, Bristol Myer... | 09/17/20 |
| When Bristol Myers Squibb picked up Celgene for $74 billion last year, analysts wondered if it was worth the price???and they specifically called out ... | |
| MPM Capital Bolsters Senior Team with Ap... | 09/17/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Former Bristol Myers Squibb Executive Matt Roden joins MPM Capital as an Executive Partner | |
| Dr. Reddy's Laboratories announces settl... | 09/17/20 |
| HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy???s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiarie... | |
| Bristol Myers settles Revlimid patent di... | 09/17/20 |
| Bristol Myers Squibb (NYSE:BMY) has settled its patent infringement litigation against Dr. Reddy's Laboratories (NYSE:RDY) related to the latter's U.S... | |
| Bristol Myers Squibb Announces Settlemen... | 09/17/20 |
| NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID?? (lenalidomide) With Dr. Reddy??... | |
| Tech startup founders looking to raise n... | 09/16/20 |
| Summary List Placement European tech investors have dry powder to deploy. The coronavirus pandemic does not appear to have siphoned funds away from Eu... | |
| Following a Delayed Launch, Bristol Myer... | 09/16/20 |
| EXTON, Pa., Sept. 16, 2020 /PRNewswire/ -- With expanded use of new oral disease-modifying therapies (DMTs) in the multiple sclerosis (MS) market, ora... | |
| The Bristol-Myers CVR Is Worth $7.83 (NY... | 09/15/20 |
| Bristol-Myers disclosed some market moving information on a Citigroup call. We are getting close to the deadline for Liso-cel and the manufacturing fa... | |
| EMA accepts Bristol Myers application fo... | 09/15/20 |
| The European Medicines Agency (EMA) has accepted for review a supplemental marketing application from Bristol Myers Squibb (NYSE:BMY) seeking approval... | |
| Obsidian Therapeutics Announces Bristol ... | 09/15/20 |
| CAMBRIDGE, Mass., Sept. 15, 2020 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies,... | |
| European Medicines Agency Validates Bris... | 09/15/20 |
| PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--European Medicines Agency Validates BMS's Type II Variation Application for Opdivo Plus Yervoy for Fir... | |
| Bristol Myers Squibb Announces Quarterly... | 09/10/20 |
| NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Quarterly Dividend for Third Quarter 2020 | |
| Compugen Starts Dosing In Early-Stage Co... | 09/09/20 |
| Israel-based cancer immunotherapy firm Compugen announced that the first patient has been dosed in the Phase 1/2 study of COM701 with Bristol Myers ??... | |
| Celgene CVR down 20% on potential delay ... | 09/08/20 |
| The Contingent Value Right (CVR) (NYSE:BMY.RT) associated with Bristol Myers Squibb's (BMY -2.2%) $74B takeover of Celgene is down ~24% today in appar... | |
| Author Of 'Delhi Riots 2020: The Untold ... | 09/03/20 |
| Ms. Monika Arora has filed a criminal complaint against Bloomsbury Publishing India Pvt. Ltd. for 'deliberately leaking the PDF version' of her book D... | |
| Bristol Myers Squibb to Participate in C... | 09/02/20 |
| NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in Citi???s 15th Annual BioPharma Virtual Conference | |
| Bristol Myers Scores FDA Nod For Acute M... | 09/02/20 |
| Bristol Myers Squibb (BMY) has announced that the U.S. The post Bristol Myers Scores FDA Nod For Acute Myeloid Leukemia Treatment appeared first on Sm... | |
| Attention Biotech Investors: Mark Your C... | 09/01/20 |
| August was a disappointing month as far as regulatory decisions are concerned. The FDA turned down several applications, citing different reasons. Not... | |
| Bristol Myers Squibb Announces Interim R... | 09/01/20 |
| PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Announces Interim Results from Long-Term Study Reinforcing Efficacy and Safety Profile of Zeposia ... | |
| Bristol Myers' enasidenib fails to exten... | 08/25/20 |
| A Phase 3 clinical trial, IDHENTIFY, evaluating Bristol Myers Squibb (NYSE:BMY) unit Celgene's IDHIFA (enasidenib) plus best supportive care (BSC) com... | |
| Bristol Myers Squibb Provides Update on ... | 08/25/20 |
| Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia | |
| Bristol Myers Squibb to acquire protein ... | 08/24/20 |
| Bristol Myers Squibb (NYSE:BMY) has agreed to acquire privately held Forbius, a clinical-stage protein engineering company with a line-up of candidate... | |
| Bristol Myers Squibb, Foundation commit ... | 08/12/20 |
| The commitment will fund initiatives to address health disparities, increase clinical trial diversity, grow the company's spend with diverse suppliers... | |
| Strong Buy rating | 08/14/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $66.00 to $67.00 | |
| Strong Buy rating | 08/12/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $64.00 to $66.00 | |
| Strong Buy rating | 07/28/20 |
| Raymond James initiates coverage with Outperform rating and announces Price Target of $75.00 | |
| Date | 2020-08-06 (BMO) | Est. (EPS/Rev.) | $1.48/ 9.97B |
| Actual (EPS/Rev.) | $1.63/ $10.13 B | EPS (TTM) | 0.81 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Options Eagle | George | 79.00 % | Follow |
| Option Superstars | James Catzen | 75.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| optionguy | Vipul Champaneri | 66.00 % | Follow |
| Options Marc | Marc M | 55.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
